Wegovy (semaglutide) is prescribed at higher doses than Ozempic for weight loss, increasing concerns about severe gastrointestinal motility disorders in some patients.
Wegovy medication often leads to gastrointestinal motility problems because of slowed gastric emptying. The slowed gastric emptiyng is what causes the fullness feeling- leading to loss of weight. Most motility disorders are known to be mild in nature. However Wegovy side effects can result in serious, devastating and rare conditions such as gastroparesis (stomach paralysis), ileus (bowel blockage), and severe constipation or severe diarrhea. These side effects can get better when doses are adjusted or Wegovy meds are discontinued. Wegovy side effects usually happen when a patient initially commences a Wegovy script. Side effects are known to get worse when dosage is increased. Side effects typically get better over time.
Infamous Motility-side Effects
- Nausea,
- constipation,
- diarrhea,
- vomiting,
- abdominal pain
- Gastroparesis (Stomach Paralysis):
- Intestinal Blockage/Ileus:
- Gallstones & Pancreatitis:
Motility Disorders and Wegovy
Wegovy’s mechanism intentionally slows digestion. In some users, this may escalate into:
- gastroparesis
- bowel shutdown
- severe constipation
- generalized dysmotility
Why Higher Doses Matter
Higher doses may:
- intensify gastric slowing
- prolong intestinal transit time
- overwhelm compensatory mechanisms
Some patients report symptoms worsening with each dose increase.
Symptoms Reported by Wegovy Users
- vomiting lasting weeks or months
- inability to eat solid foods
- abdominal swelling
- prolonged constipation
- repeated ER visits
Medical and Legal Significance
These injuries often involve:
- hospitalization
- objective diagnostic testing
- long-term impairment
They are now included in GLP-1 motility-based legal claims.
When to Seek a Review
➡️ If symptoms persisted after stopping Wegovy or required hospital care, a claim review may be appropriate.
➡️ Start here: File a Claim
Wegovy-related motility disorders represent a serious risk for a subset of patients, particularly at higher doses. These cases are now central to GLP-1 GI litigation.